+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Psoriatic Arthritis Pipeline Drugs and Companies, 2021- Phase, Mechanism of Action, Route, Licensing/Collaboration, Pre-clinical and Clinical Trials

  • PDF Icon


  • 70 Pages
  • November 2021
  • Region: Global
  • VPA Research
  • ID: 5463844
Psoriatic Arthritis pipeline drugs and companies, 2021- Phase, Mechanism of Action, Route, Licensing/collaboration, pre-clinical and clinical trials

The global comprehensive report on “Psoriatic Arthritis pipeline drugs and companies” presents key-decision makers with critical insights into Psoriatic Arthritis pipeline data. It provides complete analysis on pipeline drugs detailing Phases, route of administration, mechanism of action, licensing and collaborations, clinical trial details including pre-clinical phase and clinical trials.

Psoriatic Arthritis pipeline Drug Snapshot, 2021

The Psoriatic Arthritis pipeline study analyzes and monitors the development landscape with the current status of each of the pipeline drugs under development for Psoriatic Arthritis. In addition to recent status, overview of drugs is included in the study. Wide range of Psoriatic Arthritis drug related details including of company, indication, country, current status, drug alternative names, originator, orphan drug status, fast track details and others are provided.

Psoriatic Arthritis drug development pipeline by phase

The Psoriatic Arthritis pipeline study monitors the progress of new drug programs and provides analysis of phases, covering drugs from discovery to launch including discovery stage, preclinical, phase 1, phase 2, phase 3, pre-registration and other phases. The drug development stage for all Psoriatic Arthritis pipeline candidates is provided in the report enables you to understand timetable developments in Psoriatic Arthritis therapeutic area.

Psoriatic Arthritis pipeline drug Technology, Licensing and Collaboration Details

Details of technologies used for development of Psoriatic Arthritis pipeline candidates, licensing and collaboration agreements, partnership and other announcements, regulatory approval and other details are included in the Psoriatic Arthritis research study. Companies looking to partner with other players are also detailed in the report.

Psoriatic Arthritis- mechanism of action of pipeline candidates

Psoriatic Arthritis pipeline guide details the mechanism of action of each of the drug candidate under development. Further, leading types of mechanism of action (MoA) targeted by different Psoriatic Arthritis companies are identified to support decision makers target the most potential drugs under development.

Further, route of administration including oral, topical, sub-cutaneous, IV, ophthalmic and others are provided to assist researchers to understand most sought and least sought route of Psoriatic Arthritis drug administration.

Psoriatic Arthritis Drugs- Preclinical and Clinical Trials

This chapter in Psoriatic Arthritis preclinical and clinical trials assists in gaining clear understanding of the timetable developments in Psoriatic Arthritis product area. Preclinical and clinical trial details of pipeline candidates for Psoriatic Arthritis are detailed in the report. Details including participants, duration, companies, locations and others are provided for the trials.

Psoriatic Arthritis companies and Profiles

Companies developing Psoriatic Arthritis pipeline products are analyzed in the industry report, presenting details of business overview, location, and year of establishment, contacts, key employees, and a brief business profile.

Psoriatic Arthritis Market Developments

The report presents the recent news and developments in the Psoriatic Arthritis pipeline industry. Progress of candidates, mergers, acquisitions, asset transactions, licensing, collaborations, partnership and joint ventures, regulatory approvals, marketing and other relevant news and deals are discussed in the report.

Reasons to Buy

  • Make better-informed decisions based on the current status of each of the pipeline drug candidate
  • Identify new business opportunities by evaluating the progress of the Psoriatic Arthritis R&D pipeline
  • Analyze the market and research segments based on a comprehensive analysis of Psoriatic Arthritis pipeline drugs and clinical trials
  • Identify Psoriatic Arthritis drug pipeline trends based on consistently delivered hands on pipeline and clinical trials information
  • Gain clear understanding of the Psoriatic Arthritis drugs through our expert coverage and in-depth analysis of drugs, companies and market trends
  • Check the Psoriatic Arthritis pipeline progress of target companies and key strategies of leading players
  • Gain real-time insights into the global Psoriatic Arthritis pipeline news, developments and insights

Scope of the Report

  • Disease overview including Psoriatic Arthritis symptoms, widely used treatment options, companies and other details are included
  • Psoriatic Arthritis Pipeline Summary including the dominant phase type, number of drug candidates progressing to advanced phases, early stage pipeline candidates, leading companies, dominant route of mechanism and route of administration and other details are provided.
  • Psoriatic Arthritis pipeline drug count by phase, company and mechanism of action
  • Psoriatic Arthritis companies investing R&D resources in pipeline
  • Dominant Mechanism of Action
  • Most researched route of administration
  • For each pipeline candidate, drug, originator, co-developers, other companies, special status, phase, synonym, current status and other details are included
  • Clinical trial information for each Psoriatic Arthritis pipeline candidate are provided including preclinical, phase 1, phase 2 and phase 3 details
  • Psoriatic Arthritis companies including their business snapshot, business description and Psoriatic Arthritis pipelines are included.
  • Recent Psoriatic Arthritis market developments, pipeline news and deals are provided

Table of Contents

1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Executive Summary
2.1 Psoriatic Arthritis Disease overview
2.2 Companies investing in Psoriatic Arthritis industry
3 Psoriatic Arthritis Pipeline Snapshot, 2021
3.1 Psoriatic Arthritis Pipeline Drugs- Dominant phase type
3.2 Psoriatic Arthritis pipeline Drugs- Leading Mechanism of Action
3.3 Psoriatic Arthritis Pipeline Drugs- Widely researched Route of Administration
3.4 Psoriatic Arthritis Pipeline- New Molecular Entity
3.5 Psoriatic Arthritis pipeline- Companies, Universities and Institutes
4. Psoriatic Arthritis Drug Profiles
4.1 Current Status of Psoriatic Arthritis Drug Candidates, 2021
4.2 Psoriatic Arthritis Drugs in Development- Originator/Licensor
4.3 Psoriatic Arthritis Drugs in Development- Route of Administration
4.4 Psoriatic Arthritis Drugs in Development- New Molecular Entity (NME)
5. Psoriatic Arthritis Clinical Trials
5.1 Preclinical Trial details
5.2 Phase 1 Clinical Trial Details
5.3 Phase 2 Clinical Trial Details
5.4 Phase 3 Clinical Trial Details
6. Psoriatic Arthritis Companies and Universities
6.1 Leading Psoriatic Arthritis companies researching in drug development
6.2 Leading Psoriatic Arthritis Universities/Institutes investing in drug development
7. Psoriatic Arthritis News and Deals
7.1 Recent Psoriatic Arthritis Market Developments
7.2 Pipeline Drug News Updates
7.3 Pipeline Company updates
8. Appendix
8.1 Sources and Research Methodology
8.2 Online Database
8.3 Primary and Secondary Methodology
8.4 Customization options
8.5 Contact